Table 2.

Comorbidities of study patients in short-term randomized, controlled TRD trials

	Number (%) of patients
	TRANSFORM-1/TRANSFORM-2			TRANSFORM-3
Comorbidities	Women N = 379	Men N = 186	Total N = 565	Women N = 85	Men N = 52	Total N = 137
Anxietya	272 (71.8%)	132 (71.0%)	404 (71.5%)	NA	NA	NA
Incidental surgery	166 (43.8%)	55 (29.6%)	221 (39.1%)	37 (43.5%)	19 (36.5%)	56 (40.9%)
Hypertension	79 (20.8%)	38 (20.4%)	117 (20.7%)	46 (54.1%)	28 (53.8%)	74 (54.0%)
Allergies	69 (18.2%)	31 (16.7%)	100 (17.7%)	11 (12.9%)	4 (7.7%)	15 (10.9%)
Thyroid disease	57 (15.0%)	10 (5.4%)	67 (11.9%)	23 (27.1%)	6 (11.5%)	29 (21.2%)
GERD	48 (12.7%)	15 (8.1%)	63 (11.2%)	13 (15.3%)	8 (15.4%)	21 (15.3%)
Trauma	27 (7.1%)	31 (16.7%)	58 (10.3%)	5 (5.9%)	3 (5.8%)	8 (5.8%)
Cardiovascular disease	24 (6.3%)	13 (7.0%)	37 (6.5%)	10 (11.8%)	12 (23.1%)	22 (16.1%)
Diabetes	25 (6.6%)	8 (4.3%)	33 (5.8%)	13 (15.3%)	13 (25.0%)	26 (19.0%)
Oncology	13 (3.4%)	5 (2.7%)	18 (3.2%)	16 (18.8%)	11 (21.2%)	27 (19.7%)
Skin disorder	23 (6.1%)	13 (7.0%)	36 (6.4%)	3 (3.5%)	4 (7.7%)	7 (5.1%)
Infection	25 (6.6%)	6 (3.2%)	31 (5.5%)	2 (2.4%)	2 (3.8%)	4 (2.9%)
Respiratory disease	12 (3.2%)	2 (1.1%)	14 (2.5%)	1 (1.2%)	0	1 (0.7%)
Parathyroid disease	2 (0.5%)	1 (0.5%)	3 (0.5%)	0	1 (1.9%)	1 (0.7%)

Data presented in descending order of frequency for all patients

GERD gastroesophageal reflux disease; NA not available; TRD treatment-resistant depression

^aComorbid anxiety defined by one of the following at screening: generalized anxiety disorder current, panic disorder current, social anxiety disorder current, post-traumatic stress disorder current, or obsessive–compulsive disorder current by MINI, or having GAD-7 total score ≥ 10 at screening and at baseline. GAD-7 was not conducted in the TRANSFORM-3 study